Novel molecular target therapy for pancreatic cancer

点击翻译按钮获取中文摘要

There was a positive correlation between the clinical efficacy by gemcitabine and the expression of deoxycytidine kinase in pancreatic cancer. The majority of pancreatic cancers showed overexpression of HER2 and/or EGFR. Consequently, lapatinib, a molecular targeting agent for both of HER2 and EGFR, may be effective for pancreatic cancer. In vitro and in vivo experimental results demonstrated the substantial anti-tumor effect for pancreatic cancer by lapatinib alone and combined with S-1. It was suggested that the anti-tumor effect of lapatinib was associated with HER2 expression.